Markets US
Amgen's Imdelltra, when combined with AstraZeneca's Imfinzi, reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, according to late-stage trial results presented at the European Society for Medical Oncology Congress.
The combination therapy extended median overall survival to 21.1 months compared to 12.7 months with Imfinzi alone, as reported by Amgen. The trial tested the drug duo as maintenance therapy for patients who had not progressed after initial treatment with Imfinzi and chemotherapy. The 58% mortality reduction could shift small cell lung cancer from a rapidly fatal disease to a manageable chronic condition, according to the study.
Imdelltra generated $288 million in sales during the second quarter, up 115% year over year, with global sales reaching $627 million in 2025. Nearly 80% of patients on the combination therapy were alive at one year, compared to 53% on Imfinzi alone. The results may position Imdelltra as a first-line treatment, potentially surpassing the $1 billion sales threshold.
The data could accelerate regulatory approvals and broaden the drug's indications, enhancing Amgen's market position in oncology. However, Dr. Jacob Sands noted that the 21-month median survival figure may improve with longer-term follow-up data. The study did not compare the combination to other first-line treatments, leaving uncertainty about its relative efficacy.
Amgen and AstraZeneca are directly affected, with patients and healthcare providers likely to benefit from the improved survival rates. Investors in biotech and oncology sectors may see increased demand for Amgen's drug. The combination's efficacy across subgroups, including brain and liver metastases, suggests broad applicability, creating commercial opportunities.
The trial results may drive adoption rates, but further long-term data will be needed to confirm sustained benefits. Amgen may seek regulatory approvals to expand Imdelltra's use in earlier treatment stages, according to the Brief.
Further long-term follow-up data on patients will be needed to confirm sustained benefits. Amgen may seek regulatory approvals to expand Imdelltra's use in earlier treatment stages.
Amgen's Imdelltra combination therapy demonstrated a 58% reduction in lung cancer mortality risk, marking a potential paradigm shift in treatment. However, long-term survival data may still evolve, creating uncertainty about its full impact.
Topics: Biotechnology, Oncology, Drug Development, Cancer Treatment, Clinical Trials, Healthcare Innovation, Pharmaceutical Industry, Medical Oncology, Lung Cancer, Amgen
#Amgen #CancerTreatment #DrugCombination #Oncology #LungCancer #BiotechInnovation #ClinicalTrials #Healthcare
Source: CNBC
Post a Comment
Post a Comment